BlackRock, Inc. 13D and 13G filings for Supernus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-04-22 08:27 am Sale | 2025-03-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN | BlackRock Inc. BLK | 8,197,023 14.700% | -2,184,295 (-21.04%) | Filing |
| 2024-01-19 2:40 pm Purchase | 2023-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN | BlackRock Inc. BLK | 10,381,318 19.000% | 777,245 (+8.09%) | Filing |
| 2023-01-23 3:52 pm Purchase | 2022-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN | BlackRock Inc. BLK | 9,604,073 17.800% | 1,153,051 (+13.64%) | Filing |
| 2022-01-27 5:14 pm Unchanged | 2021-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN | BlackRock Inc. BLK | 8,451,022 15.900% | 0 (Unchanged) | Filing |
| 2022-01-26 09:16 am Sale | 2021-12-31 | 13G | Supernus Pharmaceuticals, Inc. SUPN | BlackRock Inc. BLK | 8,451,022 15.900% | -461,779 (-5.18%) | Filing |